Projects funded by the NCN
Immunological and molecular characteisitics of chronic myeloid leukemia patients after stopping imatinib
2018/31/B/NZ6/03361
Keywords:
chronic myeloid leukemia imatinib
Descriptors:
- NZ6_2:
- NZ5_3:
- NZ5_7:
Panel:
NZ6 - Human and animal immunology and infection: immunity, immune disorders, immunotherapy, infectious and invasive diseases, microbiology, transplantology, allergology
Host institution :
Uniwersytet Medyczny w Lublinie, Wydział Lekarski
woj. lubelskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 5
Call: OPUS 16 - announced on 2018-09-14
Amount awarded: 1 135 680 PLN
Project start date (Y-m-d): 2019-07-22
Project end date (Y-m-d): 2023-07-21
Project duration:: 48 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (2)
- Articles in post-conference publications (1)
- Treatment-free remission - a new aim in the treatment of chronic myeloid leukemiaAuthors:Paulina Kwaśnik, Krzysztof GiannopoulosAcademic press:Journal of Personalized Medicine (rok: 2021, tom: 11(8), 697, strony: 45682), Wydawca: MDPIStatus:PublishedDOI:10.3390/jpm11080697 - link to the publication
- High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib DiscontinuationAuthors:Paulina Kwaśnik, Joanna Zaleska, Dorota Link-Lenczowska, Magdalena Zawada, Hubert Wysogl, Bogdan Ochrem, Grażyna Bober, Ewa Wasilewska, Iwona Hus, Monika Szarejko, Witold Prejzner, Olga Grzybowska-Izydorczyk, Agnieszka Klonowska- Szymczyk, Ewa Mędraś, Michał Kiełbus,Tomasz Sacha and Krzysztof GiannopoulosAcademic press:Cells (rok: 2024, tom: 13(8), strony: 723), Wydawca: MDPIStatus:PublishedDOI:10.3390/cells13080723 - link to the publication
- IMMUNE FACTORS MAINTAINING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIBAuthors:Kwaśnik, P.; Zaleska, J.; Link-Lenczowska, D.; Zawada, M.; Ochrem, B.; Bober, G.; Wasilewska, E.; Mędraś, E.; Hus, I.; Szarejko, M.; Prejzner, W.; Grzybowska-Izydorczyk, O.; Klonowska-Szymczyk, A; Sacha, T.; Giannopoulos, KConference:European Haematology Association (rok: 2022, ), Wydawca: Wolters Kluwer HealthData:konferencja 6,2022Status:Published